Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI

Cassie Jarvis, Zhenfu Han, Vasilios Kalas, Roger Klein, Jerome S. Pinkner, Bradley Ford, Jana Binkley, Corinne K. Cusumano, Zachary Cusumano, Laurel Mydock-Mcgrane, Scott J. Hultgren, James W. Janetka

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Uropathogenic E. coli (UPEC) employ the mannose-binding adhesin FimH to colonize the bladder epithelium during urinary tract infection (UTI). Previously reported FimH antagonists exhibit good potency and efficacy, but low bioavailability and a short half-life in vivo. In a rational design strategy, we obtained an X-ray structure of lead mannosides and then designed mannosides with improved drug-like properties. We show that cyclizing the carboxamide onto the biphenyl B-ring aglycone of biphenyl mannosides into a fused heterocyclic ring, generates new biaryl mannosides such as isoquinolone 22 (2-methyl-4-(1-oxo-1,2-dihydroisoquinolin-7-yl)phenyl α-d-mannopyranoside) with enhanced potency and in vivo efficacy resulting from increased oral bioavailability. N-Substitution of the isoquinolone aglycone with various functionalities produced a new potent subseries of FimH antagonists. All analogues of the subseries have higher FimH binding affinity than unsubstituted lead 22, as determined by thermal shift differential scanning fluorimetry assay. Mannosides with pyridyl substitution on the isoquinolone group inhibit bacteria-mediated hemagglutination and prevent biofilm formation by UPEC with single-digit nanomolar potency, which is unprecedented for any FimH antagonists or any other antivirulence compounds reported to date.

Original languageEnglish
Pages (from-to)367-373
Number of pages7
JournalChemMedChem
Volume11
Issue number4
DOIs
StatePublished - Feb 17 2016

Keywords

  • FimH
  • biofilms
  • mannosides
  • urinary tract infections
  • uropathogenic E. coli

Fingerprint

Dive into the research topics of 'Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI'. Together they form a unique fingerprint.

Cite this